Jeffrey E. Lancet, MD of Moffitt Cancer Center presents Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial at the 58th ASH Annual Meeting in San Diego, CA.
Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk AML Patients
